Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28695
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBoktor, Raef R-
dc.contributor.authorLee, Sze Ting-
dc.contributor.authorBerlangieri, Salvatore U-
dc.contributor.authorScott, Andrew M-
dc.date.accessioned2022-02-01T04:44:38Z-
dc.date.available2022-02-01T04:44:38Z-
dc.date.issued2022-
dc.identifier.citationAsia Oceania Journal of Nuclear Medicine & Biology 2022; 10(1): 20-27en
dc.identifier.issn2322-5718
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/28695-
dc.description.abstract18F-FDG PET/CT is increasingly performed in patients with differen-tiated thyroid cancer. The aim of this study was to assess the clinical impact of 18F-FDG PET/CT on the management of patients with differentiated thyroid carcinoma who had elevated serum thyroglobulin (Tg) and negative 131I whole body scan (WBS). 67 patients with differentiated thyroid carcinoma were included in this study. The findings of 18F-FDG PET/CT imaging were compared with histo-pathology, follow up imaging, or clinical follow-up results. The diagnostic accuracy of 18F-FDG PET/CT was evaluated for the entire patient group and for those patients with stimulated serum thyroglobulin levels of less than 5, 5-10, and more than 10 pmol/L as well as for local recurrences and metastases sites. The impact of 18F-FDG PET/CT on therapeutic management was also evaluated. 30/67 patients had positive findings on 18F-FDG PET/CT; 28 were true-positive and 2 were false-positive. 18F-FDG PET/CT results were true-negative in 36 patients and false-negative in 1 patient. The overall sensitivity, specificity, accuracy, PPV and NPV of 18F-FDG PET/CT were, 96.5%, 94.5%, 95.5%, 93.3%, and 97.2% respectively. Positive 18F-FDG PET/CT findings were directly correlated with stimulated serum thyroglobulin levels, 7.1% had Tg between 5-10, and 92.9% had Tg greater than 10 pmol/L. 18F-FDG PET/CT had a high or moderate impact on treatment management in 28 (41.8%) of patients. 18F-FDG PET/CT is able to improve diagnostic accuracy and have management impact in a therapeutically relevant way in patients with differentiated thyroid carcinoma who present with rising thyroglobulin level, negative 131I WBS, and clinical suspicion of recurrent disease.en
dc.language.isoeng
dc.subject131Ien
dc.subjectFDG PETen
dc.subjectThyroglobulinen
dc.subjectThyroid carcinomaen
dc.titleImpact of 18F-FDG PET/CT on treatment of patients with differentiated thyroid carcinoma, negative 131I whole body scan and elevated serum thyroglobulin.en
dc.typeJournal Articleen
dc.identifier.journaltitleAsia Oceania Journal of Nuclear Medicine & Biologyen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationMolecular Imaging and Therapyen
dc.identifier.affiliationFaculty of Medicine, University of Melbourne, Melbourne, VIC, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, VIC, Australiaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35083346/en
dc.identifier.doi10.22038/AOJNMB.2021.58276.1406en
dc.type.contentTexten
dc.identifier.orcid0000-0003-4861-619Xen
dc.identifier.orcid0000-0001-8641-456Xen
dc.identifier.orcid0000-0002-6656-295Xen
dc.identifier.pubmedid35083346
local.name.researcherBerlangieri, Salvatore U
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

30
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.